Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Contineum Therapeutics, Inc. Class A (CTNM – Research Report ... Morgan Stanley also maintained a Buy rating on the stock with a $25.00 ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Contineum Therapeutics, Inc. Class A (CTNM – Research Report) today and ...

Robert W. Baird started coverage on shares of Contineum Therapeutics (NASDAQ:CTNM – Free Report) in a research note issued to ...

Beatty issued a $32 price target on CTNM, arguing that the end of a mid-stage trial for PIPE-307 in relapsing-remitting multiple sclerosis (RMMS) could be a potential catalyst for the stock in 2025.

Based on data from MarketBeat.com, Contineum Therapeutics has an average rating of “Buy” and an average target price of $29.50. Shares of CTNM stock opened at $16.26 on Tuesday. Contineum ...

Fintel reports that on October 22, 2024, Baird initiated coverage of Contineum Therapeutics (NasdaqGS:CTNM) with a Outperform recommendation. Analyst Price Forecast Suggests 81.95% Upside As of ...

On Tuesday, Stifel initiated coverage on Contineum Therapeutics (NASDAQ:CTNM), a biotech firm specializing in small molecule therapies, with a Buy rating and a price target of $29.... Tuesday, Morgan ...

SAN DIEGO, CA – Contineum Therapeutics, Inc. (NASDAQ:CTNM) announced the appointment of Sarah Boyce to its board of directors, effective today. Boyce joins the board as a Class I ...